Collegium Pharmaceutical (NASDAQ:COLL) received a $26.00 price objective from equities researchers at Janney Montgomery Scott in a research report issued on Tuesday. The firm presently has a “buy” rating on the specialty pharmaceutical company’s stock. Janney Montgomery Scott’s price objective points to a potential upside of 20.93% from the stock’s current price.
Several other equities research analysts have also issued reports on the company. Zacks Investment Research lowered Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Friday. BidaskClub lowered Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Friday, January 26th. Piper Jaffray Companies set a $33.00 price target on Collegium Pharmaceutical and gave the stock a “buy” rating in a research note on Tuesday, January 23rd. Needham & Company LLC raised their price target on Collegium Pharmaceutical from $25.00 to $28.00 and gave the stock a “buy” rating in a research note on Tuesday, December 5th. They noted that the move was a valuation call. Finally, Jefferies Group raised their price target on Collegium Pharmaceutical to $27.00 and gave the stock a “buy” rating in a research note on Tuesday, December 5th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $25.17.
Shares of Collegium Pharmaceutical (NASDAQ COLL) traded up $0.15 during trading on Tuesday, reaching $21.50. The company had a trading volume of 167,704 shares, compared to its average volume of 635,805. Collegium Pharmaceutical has a 52 week low of $7.37 and a 52 week high of $26.77. The company has a market capitalization of $735.91, a price-to-earnings ratio of -7.30 and a beta of 0.80.
Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.45) EPS for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.28. The company had revenue of $11.95 million during the quarter, compared to analyst estimates of $5.31 million. Collegium Pharmaceutical had a negative return on equity of 77.11% and a negative net margin of 447.83%. The firm’s revenue was up 2814.6% on a year-over-year basis. During the same period in the prior year, the company earned ($1.13) earnings per share. research analysts anticipate that Collegium Pharmaceutical will post -2.52 EPS for the current year.
In other Collegium Pharmaceutical news, major shareholder Longitude Capital Partners, Ll sold 1,000,000 shares of the firm’s stock in a transaction on Friday, December 8th. The stock was sold at an average price of $17.34, for a total transaction of $17,340,000.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Michael Thomas Heffernan sold 50,000 shares of the firm’s stock in a transaction on Wednesday, November 15th. The stock was sold at an average price of $15.53, for a total value of $776,500.00. Following the transaction, the chief executive officer now owns 558,987 shares in the company, valued at $8,681,068.11. The disclosure for this sale can be found here. Insiders have sold a total of 1,105,558 shares of company stock worth $19,346,677 over the last 90 days. 25.76% of the stock is currently owned by company insiders.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Voya Investment Management LLC purchased a new position in shares of Collegium Pharmaceutical in the 2nd quarter valued at $125,000. Benjamin F. Edwards & Company Inc. increased its holdings in shares of Collegium Pharmaceutical by 87.5% in the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 7,500 shares of the specialty pharmaceutical company’s stock valued at $138,000 after acquiring an additional 3,500 shares during the period. Nationwide Fund Advisors increased its holdings in shares of Collegium Pharmaceutical by 27.8% in the 2nd quarter. Nationwide Fund Advisors now owns 12,889 shares of the specialty pharmaceutical company’s stock valued at $161,000 after acquiring an additional 2,802 shares during the period. Acadian Asset Management LLC purchased a new position in shares of Collegium Pharmaceutical in the 4th quarter valued at $176,000. Finally, JPMorgan Chase & Co. purchased a new position in shares of Collegium Pharmaceutical in the 3rd quarter valued at $192,000. Institutional investors own 82.29% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by Stock Observer and is owned by of Stock Observer. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at https://www.thestockobserver.com/2018/02/06/collegium-pharmaceutical-coll-pt-raised-to-26-00.html.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.